16-05-2008

Dergi Hakkında
Yayın Kurulu
Uluslararası Danışmanlar
İstatistik ve Epidemiyoloji Danışmanları
Ulusal Danışmanlar
Yazım Kuralları
Yayın Hakları Devir Formu
Online Makale İşlemleri
İletişim
Tıp Bilimleri Dergisi
ISSN: 1300-0292
İndekslendiği Dizinler: SCIENCE CITATION INDEX EXPANDED
CINAHL, Index Copernicus,
Chemical Abstracts (CA),
Excerpta Medica / EMBASE
Dil: Türkçe, İngilizce
İçerik: Orijinal Araştırma, Derleme, Editöre Mektup, Olgu Sunumu, Tıp Eğitimi, Tıbbi Kitap İncelemeleri

 

REVIEW ARTICLES


Treatment Of Myelodysplastic Syndrome

Cengiz BEYAN*, Kürşad KAPTAN**

* Doç.Dr., GATA Hematoloji BD,
** Uz.Dr., GATA Hematoloji BD, ANKARA



In myelodysplastic syndrome, it hasn't been described an effective treatment except bone marrow transplantation to date. Therefore, the treatment consists of transfusion support in most cases. However, it was reported that immunosuppressive treatment was successful in hypocelluler myelodysplasia as in aplastic anemia. Differentiating agents are not usually effective in the treatment, but isotretinoin was effective in juvenile CML. The results of with 5-azacytidine that inhibits DNA methylation is promising. Amifostine that is a antiapoptotic agent has improved cytopenia in some patients. Erytropoietin may be effective to reduce the requirement of transfusion in patients with refractory anemia or patients with low level of serum erythropoietin. Myeloid growth factors may also be effective to increase neutrophil count in patients who have recurrent infections. There is a conflict on the results of treatment with one chemotherapeutic agent. Treatment with intensive chemotherapy regimens that are administered in AML have high mortality rate with 40-70 percent complete remission (CR). These regimens may be successful in high risk patients. Allogeneic bone marrow transplantation with high mortality rate seems to be the only curative treatment modality. Autologus peripheral stem cell transplantation in patients in CR following remission induction chemotherapy has been researched. In fact, treatment of patients with MDS had to be tailored for every individual patients regarding patients characteristics.

Keywords: Myelodysplastic Syndromes, Therapeutics, Growth Substances, drug therapy, Bone Marrow Transplantation

Turkiye Klinikleri J Med Sci 2001, 21:124-130

E-mail To Friend This Page Printer Friendly Page
 
 
 ARAMA
  
 Ayrıntılı Arama
 GİRİŞ
 Kullanıcı Adı :
 
 Şifre  
   Beni Hatırla
 Şifremi Unuttum
 Kayıt Ol
 
 
 
 
 
 
 
 

Yasal uyarı: Bu sitede yayınlanan resim, yazı ve diğer uygulamaların her hakkı Ortadoğu Reklam Ve Yayıncılık A.Ş. 'ye aittir. Kaynak gösterilmeden kullanılamaz. Bu site hekimleri sağlık alanında bilgilendirmeye yönelik hazırlanmıştır. Sitede yer alan bilgiler tanı ve tedavi amaçlı kullanıldığında sorumluluk tamamen kullanıcıya aittir. Siteye girmekle bu şartları okumuş, anlamış ve kabul etmiş sayılırsınız.